Nanoparticles coated with PD-1/PD-L1-targeted ligands have become a new drug delivery system which can improve the drug delivery effect, enhance the immune response, and reduce the side effects of tumor treatment [186,187,188]. This evidence concerns the gene CD274 and neoplasm.